Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Toni K. Choueiri, MD, on KEYNOTE-564: Pembrolizumab in the Adjuvant Treatment of Renal Cell Carcinoma

Posted: Monday, June 7, 2021

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the clinical implications of findings from the phase III KEYNOTE-564 study. He also offers some clinical pearls on the length of pembrolizumab treatment in patients with renal cell carcinoma and whether a checkpoint inhibitor in the adjuvant setting will preclude its use if or when disease becomes metastatic.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.